Over expressing miR-19b-1 suppress breast cancer growth by inhibiting tumor microenvironment induced angiogenesis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Metastatic breast cancer, particularly triple-negative breast cancer (TNBC), is a significant cause of cancer mortality in women.
• Tumor angiogenesis, the formation of new blood vessels, is a critical process in cancer progression and a potential therapeutic target.
• Previous research identified miR-19b-1 as a regulator of endothelial cell angiogenic activity.

Purpose of the Study:

• To investigate the role of miR-19b-1 in triple-negative breast cancer progression and angiogenesis.
• To identify potential targets of miR-19b-1 involved in angiogenesis and TNBC.
• To explore the therapeutic potential of miR-19b-1 in metastatic breast cancer.

Main Methods:

• In silico analysis to predict miR-19b-1 targets.
• Overexpression of miR-19b-1 in MDA-MB-231 (TNBC) and human umbilical vein endothelial cells (HUVECs).
• In vitro and in vivo assays to assess angiogenic activity, cell apoptosis, mitochondrial membrane potential, and tumor growth.

Main Results:

• In silico analysis identified VEZF1 as a potential target of miR-19b-1.
• Overexpression of miR-19b-1 in MDA-MB-231 cells impaired HUVEC angiogenic activity in vitro and in vivo.
• miR-19b-1 upregulation inhibited MDA-MB-231-mediated angiogenesis, induced HUVEC apoptosis, altered mitochondrial membrane potential, and completely arrested tumor growth.
• miR-19b-1 may inhibit angiogenesis by targeting the VEGF receptor endocytosis signaling pathway.

Conclusions:

• miR-19b-1 plays a crucial role in the crosstalk between metastatic breast cancer cells and endothelial cells.
• miR-19b-1 acts as a tumor suppressor by inhibiting angiogenesis and tumor growth in TNBC.
• miR-19b-1 and its targets represent promising therapeutic candidates for interfering with breast cancer progression.